Deubiquitinase PSMD14 promotes tumorigenicity of glioblastoma by deubiquitinating and stabilizing β‐catenin
BioFactors · 2024
DOI: 10.1002/biof.2061 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioFactors, 2024. Verfasst von Yang Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Glioblastoma, beta Catenin, Ubiquitination, Proteasome Endopeptidase Complex. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Jiangsu Province's Natural Science Foundation, Jiangsu Funding Program for Excellent Postdoctoral Talent, National Natural Science Foundation of China.
Abstract (Originalsprache)
The deubiquitinating enzyme 26S proteasome non‐ATPase regulatory subunit 14 (PSMD14), a member of the JAB1/MPN/Mov34 metalloenzyme (JAMM) family, has been shown to function as an oncogene in various human cancers. However, the function of PSMD14 in glioma and the underlying mechanism remain unclear. In this study, our findings reveal a dramatic upregulation of PSMD14 in GBMs, which is associated with poor survival outcomes. Knocking down PSMD14 is associated with decreased proliferation and invasion of GBM cells in vitro and inhibited tumor growth in a xenograft mouse model. Mechanistically, PSMD14 directly interacts with β‐catenin, leading to a decrease in the K48‐linked ubiquitination of β‐catenin and subsequent β‐catenin stabilization. Increased β‐catenin expression significantly reverses the inhibitory effects of PSMD14 knockdown on the migration, invasion, and tumor growth of GBM cells. Moreover, we observed a significant correlation between PSMD14 and β‐catenin expression in human GBM samples. In summary, our results reveal that PSMD14 is a crucial deubiquitinase that is responsible for stabilizing the β‐catenin protein, highlighting its potential for use as a therapeutic target for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Huaian Hospital of Huaian City, Huaian Cancer Hospital, China.
- Department of Neurosurgery, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of Neurosurgery, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, China.
ORCID-Profile: Yang Wang
Förderung
- Jiangsu Province's Natural Science Foundation
- Jiangsu Funding Program for Excellent Postdoctoral Talent
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Liu, Y., Ma, C., Liu, C., Tang, Q., Wang, Z., Lu, J., Chen, Z., & Wang, H. (2024). Deubiquitinase PSMD14 promotes tumorigenicity of glioblastoma by deubiquitinating and stabilizing β‐catenin. BioFactors. https://doi.org/10.1002/biof.2061
Vancouver
Wang Y, Liu Y, Ma C, Liu C, Tang Q, Wang Z, et al. Deubiquitinase PSMD14 promotes tumorigenicity of glioblastoma by deubiquitinating and stabilizing β‐catenin. BioFactors. 2024. doi:10.1002/biof.2061
BibTeX
@article{Wang2024,
author = {Wang, Yang and Liu, Yu and Ma, Chongchen and Liu, Cen and Tang, Qikai and Wang, Zhangjie and Lu, Jiacheng and Chen, Zhengxin and Wang, Huibo},
title = {Deubiquitinase PSMD14 promotes tumorigenicity of glioblastoma by deubiquitinating and stabilizing β‐catenin},
journal = {BioFactors},
year = {2024},
doi = {10.1002/biof.2061}
}
EUVIMED